Latest News

Uncategorized

ESMO 2019: Pembrolizumab with Enzalutamide in mCRPC: Examination of Tumor Infiltrating Immune Cells and Fecal Microbiota, A Phase II Study – A Medical Oncologist’s Perspective

Barcelona, Spain (UroToday.com) Relative to other solid tumors, prostate cancer is viewed as an immunologically “cold” tumor with less robust responses to immunotherapy than other malignancies. Early data from trials of immunotherapy in metastatic castration-resistant prostate cancer (mCRPC) do however suggest that a small percentage of patients respond to this approach and may have durable benefit.  […]

Uncategorized

ESMO 2019: APACHE: An Open Label, Randomized, Phase 2 Study of Durvalumab, Alone or in Combination with Tremelimumab, in Patients with Refractory Germ Cell Tumors: Results from the Expanded Combination Therapy Cohort 

Barcelona, Spain (UroToday.com) Refractory disease represents a critical issue in germ cell tumor (GCT) management with < 5% of patients surviving. Many chemotherapeutic and targeted treatment strategies have been evaluated with low response rates highlighting an urgent need for new treatment options in this clinical setting. APACHE (NCT03081923) is an open label, phase 2 study […]

Uncategorized

Health-Related Quality Of Life After Apalutamide Treatment In Patients with Metastatic Castration-Sensitive Prostate Cancer (TITAN): A Randomised, Placebo-Controlled, Phase 3 Study

Background: In the phase 3 TITAN study, the addition of apalutamide to androgen deprivation therapy (ADT) significantly improved the primary endpoints of overall survival and radiographic progression-free survival in patients with metastatic castration-sensitive prostate cancer. We aimed to assess health-related quality of life (HRQOL) in TITAN, including pain and fatigue. Methods: In this randomised, placebo-controlled, […]

Uncategorized

ESMO 2019: Multiple-cohort Analysis Investigating FGFR3 Alteration as A Predictor of Non-response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer

Barcelona, Spain (UroToday.com) PURE-01 was a single-arm phase II study of neoadjuvant immunotherapy with the PD-1 antibody pembrolizumab for the treatment of muscle invasive bladder cancer.1 Encouragingly, investigators from that trial found a 42% pathologic complete response rate and a 54% rate of pathologic downstaging to non-muscle invasive disease. The present study reports on several […]

Uncategorized

ESMO 2019: Phase II Study of Pembrolizumab with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: 30 Patient Expansion with Examination of Tumor Infiltrating Immune Cells and Fecal Microbiota

Barcelona, Spain (UroToday.com) PD-1 inhibition can lead to deep, durable responses in metastatic castration-resistant prostate cancer (mCRPC), but only in a minority of patients. Graff and colleagues previously reported five (18%) responders among 28 patients receiving pembrolizumab with enzalutamide, however, no marker has been shown to universally predict response. Analysis of fecal microbiota from patients […]

Uncategorized

ESMO 2019: Efficacy and Safety of Nivolumab in Combination With Docetaxel in Men With Metastatic Castration-Resistant Prostate Cancer in CheckMate 9KD – Medical Oncologist Perspective

Barcelona, Spain (UroToday.com) Relative to other solid tumors, prostate cancer is viewed as an immunologically “cold” tumor with less robust responses to immunotherapy than other diseases such as melanoma or lung cancer. Early data from trials of immunotherapy in metastatic castration resistant prostate cancer (mCRPC) do however suggest that a small percentage of patients respond […]

Uncategorized

Clovis Oncology Highlights Rubraca® (rucaparib) Updated Data from the Ongoing TRITON2 Clinical Trial in Patients with Metastatic Castration-Resistant Prostate Cancer and Exploratory and Integrated Analyses in Recurrent Ovarian Cancer at the ESMO Congress

San Francisco, CA (UroToday.com) — Clovis Oncology, Inc. announced updated data from the Phase 2 TRITON2 trial at the European Society for Medical Oncology (ESMO) Congress 2019, reinforcing the potential of Rubraca® (rucaparib) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) with a BRCA1/2 mutation. The data show a 43.9% confirmed objective […]

Uncategorized

ESMO 2019: Preliminary Results from the TRITON2 Study of Rucaparib in Patients with DNA Damage Repair (DDR)-deficient Metastatic Castration-resistant Prostate Cancer (mCRPC): Updated Analyses

Barcelona, Spain (UroToday.com) Up to 25% of patients with metastatic castration-resistant prostate cancer (mCRPC) harbor a deleterious germline or somatic alteration in BRCA1, BRCA2, ATM, or other DNA damage repair (DDR) gene. Emerging data suggests that PARP inhibitors show clinical activity in patients with mCRPC and BRCA1/2 alterations. The TRITON2 investigators presented updated data using an […]

Uncategorized

ESMO 2019: Pre-operative Ipilimumab and Nivolumab in Locoregionally Advanced, Stage III, Urothelial Cancer (NABUCCO) 

Barcelona, Spain (UroToday.com) While the standard of care for non-metastatic muscle-invasive bladder cancer remains neoadjuvant platinum-based chemotherapy followed by radical cystectomy, a number of recently completed and ongoing clinical trials are investigating the use of checkpoint blockade immunotherapy in this setting. Immunotherapy is an attractive neoadjuvant option given its very good safety profile and tolerability, […]

Uncategorized

ESMO 2019: A First-in-Human Phase I/II Trial of the Oral HIF-2a Inhibitor PT2977 in Patients with Advanced Renal Cell Carcinoma

Barcelona, Spain (UroToday.com) Hypoxia inducible factor 2α (HIF-2α) is known to mediate von Hippel-Lindau (VLH) associated oncogenesis. Deficiency of the VHL tumor suppressor leads to HIF-2α stabilization and intracellular accumulation, thereby promoting the formation of heterodimers with HIF-1β. These heterodimer acts as a key transcription factor for genes which promote tumorigenesis, such as VEGFA, thereby […]

X